Congestive Heart Failure (2025)

Only available as part of a package

Learning Objectives:

Upon completion, participants will be able to explain the mechanisms and benefits of various pharmacological interventions, including sodium-glucose co-transporter 2 inhibitors (SGLT2i) and ACE inhibitors, in heart failure management.
Upon completion, participants will be able to identify and differentiate between the various classification systems for heart failure, including the ACC/AHA staging and NYHA functional classification, and apply them to clinical practice.
Upon completion, participants will be able to analyze the clinical and therapeutic benefits of neprilysin inhibitors in the treatment of heart failure, including their impact on natriuretic peptide levels.

Arash Karnama, DO, FACOI

Clinical Associate Professor of Medicine

Oklahoma State University

Arash Karnama, DO is a clinical associate professor of medicine at Oklahoma State University Center for Health Sciences. He is a board certified interventional cardiologist. He received his Doctor of Osteopathic Medicine degree from Des Moines University. He completed his residency in internal medicine at Penn State Milton S. Hershey Medical Center. He completed his fellowship in cardiology and interventional cardiology at Oklahoma State University.